Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation

By LabMedica International staff writers
Posted on 27 May 2026

The TOBY Test for Alzheimer’s Disease from TOBY, Inc. More...

(Austin, TX, USA) has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation as an aid in the diagnosis of Alzheimer’s disease. The non-invasive test uses a simple urine sample and is intended for evaluating adults aged 50 years and older who have signs and symptoms of cognitive impairment. Under the proposed indication recognized by the agency, results are intended to be interpreted alongside other clinical information. The designation reflects the test’s potential to address unmet needs in accessible cognitive evaluation and diagnostic care.

The assay assesses patterns of urinary volatile organic compounds using mass spectrometry combined with proprietary machine learning algorithms. By targeting disease-associated urinary VOC signatures, the approach provides a distinctly non-invasive pathway for aiding diagnosis. In contrast to modalities that focus primarily on detecting amyloid pathology, the proposed indication for this test is to aid in the diagnosis of Alzheimer’s disease itself.

The Breakthrough Devices Program is intended to accelerate development and review of technologies that may offer more effective diagnosis or treatment for life‑threatening or irreversibly debilitating conditions. The designation enables closer interaction with the FDA throughout development and regulatory review. TOBY plans to continue clinical validation studies and work with the agency toward future regulatory submissions. This Alzheimer’s designation is the company’s third Breakthrough Device Designation, reinforcing its platform strategy in urine-based molecular diagnostics across oncology and central nervous system disease.

"This designation further validates the potential of urinary VOC patterns as an entirely new diagnostic modality," said Matthew Laskowski, Founder and CEO of TOBY. "For the millions of individuals and families living in the shadow of Alzheimer's disease, the need for earlier, simpler and more accessible detection has never been greater. This milestone reflects our commitment to the patients and families who deserve earlier and easier answers."

"Existing cleared and breakthrough-designated Alzheimer's tests are generally focused on identifying amyloid pathology associated with Alzheimer's disease, whereas the proposed indication for the TOBY Alzheimer's Test is intended to aid in the diagnosis of Alzheimer's disease itself. Our goal is to build scalable, non-invasive tests capable of transforming how serious diseases are detected and evaluated," said Laskowski.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.